Melanoma Survivorship Management

  • Genevieve Marie Boland
  • Jeffrey E. Gershenwald
Part of the MD Anderson Cancer Care Series book series (MDCCS)


Many important issues are relevant to melanoma survivors after initial melanoma diagnosis and treatment. A diagnosis of melanoma not only affects patients during the time of initial treatment, but also may play a significant role in their life for many years. These issues are broad and apply to many aspects of patients’ lives. This chapter will discuss overall and stage-specific surveillance strategies and methods for risk reduction and prevention that are important to the melanoma survivor population. It is also important for patients and care providers alike to understand and learn to manage sequelae that may accompany various melanoma treatments, from surgery to targeted therapies. Finally, this chapter will discuss issues relating to long-term survivorship such as psychosocial adjustment, reproductive issues, and health care costs.


Sentinel Lymph Node Biopsy BRAF Mutation Primary Melanoma BRAF Inhibitor Completion Lymph Node Dissection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Suggested Readings

  1. American Cancer Society. Cancer treatment and survivorship: facts and figures, 2012–2013. Accessed September 27, 2013.
  2. American Cancer Society. Cancer facts & figures 2014. Accessed June 23, 2014.
  3. Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010;28(14):2452–2459.PubMedCrossRefPubMedCentralGoogle Scholar
  4. Baughan CA, Hall VL, Leppard BJ, Perkins PJ. Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) 1993;5(3):174–180.CrossRefGoogle Scholar
  5. Boland GM, Gershenwald JE. Sentinel lymph node biopsy in melanoma. Cancer J 2012;18(2):185–191.PubMedCrossRefGoogle Scholar
  6. Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010;146(3):265–272.PubMedPubMedCentralGoogle Scholar
  7. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012;13(6):589–597.PubMedCrossRefGoogle Scholar
  8. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl J Med 2011;364(26):2507–2516.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer 2010;116(22):5138–5149.PubMedCrossRefGoogle Scholar
  10. Cormier JN, Rourke L, Crosby M, Chang D, Armer J. The surgical treatment of lymphedema: a systematic review of the contemporary literature (2004–2010). Ann Surg Oncol 2012;19(2): 642–651.PubMedCrossRefGoogle Scholar
  11. Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010;17(12):3324–3329.PubMedCrossRefPubMedCentralGoogle Scholar
  12. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl J Med 2012a;367(18):1694–1703.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl J Med 2012b;367(2):107–114.PubMedCrossRefGoogle Scholar
  14. Francken AB, Accortt NA, Shaw HM, et al. Follow-up schedules after treatment for malignant melanoma. Br J Surg 2008;95(11):1401–1407.PubMedCrossRefGoogle Scholar
  15. Gershenwald JE, Coit DG, Sondak VK, Thompson JF. The challenge of defining guidelines for sentinel lymph node biopsy in patients with thin primary cutaneous melanomas. Ann Surg Oncol 2012;19(11):3301–3303.PubMedCrossRefGoogle Scholar
  16. Gershenwald JE, Ross MI. Sentinel-lymph-node biopsy for cutaneous melanoma. New Engl J Med 2011;364(18):1738–1745.PubMedCrossRefGoogle Scholar
  17. Goggins WB, Tsao H. A population-based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors. Cancer 2003;97(3):639–643.PubMedCrossRefGoogle Scholar
  18. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010;363(8):711–723.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Kalady MF, White RR, Johnson JL, Tyler DS, Seigler HF. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg 2003;238(4):528–535.PubMedPubMedCentralGoogle Scholar
  20. Machet L, Nemeth-Normand F, Giraudeau B, et al. Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients. Br J Dermatol 2005;152(1):66–70.PubMedCrossRefGoogle Scholar
  21. Mooney MM, Mettlin C, Michalek AM, Petrelli NJ, Kraybill WG. Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer 1997;80(6):1052–1064.PubMedCrossRefGoogle Scholar
  22. Moore Dalal K, Zhou Q, Panageas KS, Brady MS, Jaques DP, Coit DG. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. Ann Surg Oncol 2008;15(8):2206–2214.PubMedCrossRefGoogle Scholar
  23. Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. Clin Exp Metastasis 2012;29(7):699–706.PubMedCrossRefPubMedCentralGoogle Scholar
  24. Morton RL, Howard K, Thompson JF. The cost-effectiveness of sentinel node biopsy in patients with intermediate thickness primary cutaneous melanoma. Ann Surg Oncol 2009;16(4):929–940.PubMedCrossRefGoogle Scholar
  25. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—melanoma, v2.2013. Accessed September 27, 2013.
  26. Nieweg OE, Kroon BB. The conundrum of follow-up: should it be abandoned? Surg Oncol Clin N Am 2006;15(2):319–330.PubMedCrossRefGoogle Scholar
  27. Pandalai PK, Dominguez FJ, Michaelson J, Tanabe KK. Clinical value of radiographic staging in patients diagnosed with AJCC stage III melanoma. Ann Surg Oncol 2011;18(2):506–513.PubMedCrossRefGoogle Scholar
  28. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med 2011;364(26):2517–2526.PubMedCrossRefGoogle Scholar
  29. Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol 2010;28(18):3042–3047.PubMedCrossRefPubMedCentralGoogle Scholar
  30. Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol 2011;104(4):341–353.PubMedCrossRefGoogle Scholar
  31. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl J Med 2012;366(26):2443–2454.PubMedCrossRefPubMedCentralGoogle Scholar
  32. Uren RF, Sanki A, Thompson JF. The utility of ultrasound in patients with melanoma. Expert Rev Anticancer Ther 2007;7(11): 1633–1642.PubMedCrossRefGoogle Scholar

Copyright information

© The University of Texas M. D. Anderson Cancer Center 2015

Authors and Affiliations

  • Genevieve Marie Boland
    • 1
  • Jeffrey E. Gershenwald
    • 1
  1. 1.Department of Surgical OncologyThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations